Personalised cancer vaccine with immunotherapy cuts risk of melanoma returning by 42%, study finds
Adding a personalised messenger RNA (mRNA) cancer vaccine to pembrolizumab — an immunotherapy drug — after surgery for high-risk melanoma reduced the risk of recurrence or death by 42%, phase III trial results have shown. During the trial — the results of which were…